Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The firm presently has a $31.00 price objective on the stock. Zacks Investment Research‘s price objective indicates a potential upside of 11.47% from the stock’s previous close.

According to Zacks, “Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company’s drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals, Inc. is based in Durham, North Carolina. “

Several other equities analysts have also commented on the stock. Leerink Swann began coverage on shares of Dova Pharmaceuticals in a research report on Monday, July 24th. They set a “market perform” rating and a $24.00 price target for the company. J P Morgan Chase & Co began coverage on shares of Dova Pharmaceuticals in a research report on Monday, July 24th. They set an “overweight” rating and a $35.00 price target for the company. Finally, Jefferies Group LLC began coverage on shares of Dova Pharmaceuticals in a research report on Monday, July 24th. They set a “buy” rating and a $30.00 price target for the company.

Dova Pharmaceuticals (NASDAQ DOVA) traded up 0.65% during trading on Wednesday, reaching $27.81. The company’s stock had a trading volume of 83,303 shares. Dova Pharmaceuticals has a 12 month low of $16.98 and a 12 month high of $29.99. The stock’s 50-day moving average is $25.66 and its 200 day moving average is $24.82. The company’s market cap is $713.38 million.

Dova Pharmaceuticals (NASDAQ:DOVA) last released its quarterly earnings results on Thursday, August 10th. The company reported ($0.32) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.08). On average, equities analysts forecast that Dova Pharmaceuticals will post ($1.40) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/11/dova-pharmaceuticals-inc-dova-upgraded-to-buy-by-zacks-investment-research.html.

In related news, Director Paul B. Manning purchased 25,870 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The shares were purchased at an average price of $22.30 per share, with a total value of $576,901.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Steven M. Goldman purchased 20,169 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was bought at an average cost of $22.23 per share, for a total transaction of $448,356.87. Following the purchase, the director now directly owns 81,158 shares in the company, valued at approximately $1,804,142.34. The disclosure for this purchase can be found here.

A number of institutional investors have recently added to or reduced their stakes in DOVA. Laurion Capital Management LP purchased a new position in Dova Pharmaceuticals in the 2nd quarter valued at $223,000. JPMorgan Chase & Co. purchased a new position in Dova Pharmaceuticals in the 2nd quarter valued at $382,000. Vanguard Group Inc. purchased a new position in Dova Pharmaceuticals in the 2nd quarter valued at $390,000. Goldman Sachs Group Inc. purchased a new position in Dova Pharmaceuticals in the 2nd quarter valued at $493,000. Finally, Ameriprise Financial Inc. purchased a new position in Dova Pharmaceuticals in the 2nd quarter valued at $668,000. 23.52% of the stock is currently owned by hedge funds and other institutional investors.

Dova Pharmaceuticals Company Profile

Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).

Get a free copy of the Zacks research report on Dova Pharmaceuticals (DOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Dova Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.